TY - JOUR
T1 - Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis
AU - Ghosal, Suman
AU - Vanova, Katerina Hadrava
AU - Uher, Ondrej
AU - Das, Shaoli
AU - Patel, Mayank
AU - Meuter, Leah
AU - Huynh, Thanh Truc
AU - Jha, Abhishek
AU - Talvacchio, Sara
AU - Knue, Marianne
AU - Prodanov, Tamara
AU - Zeiger, Martha A.
AU - Nilubol, Naris
AU - Taieb, David
AU - Crona, Joakim
AU - Shankavaram, Uma T.
AU - Pacak, Karel
N1 - Funding Information:
NanoString analysis was conducted at the CCR Genomics Core at the National Cancer Institute, NIH, Bethesda, MD 20892.
Funding Information:
This research was supported by the Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).
Publisher Copyright:
© 2022, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
PY - 2023/1
Y1 - 2023/1
N2 - Purpose: To understand prognostic immune cell infiltration signatures in neuroendocrine neoplasms (NENs), particularly pheochromocytoma and paraganglioma (PCPG), we analyzed tumor transcriptomic data from The Cancer Genome Atlas (TCGA) and other published tumor transcriptomic data of NENs. Methods: We used CIBERSORT to infer immune cell infiltrations from bulk tumor transcriptomic data from PCPGs, in comparison to gastroenteropancreatic neuroendocrine tumors (GEPNETs) and small cell lung carcinomas (SCLCs). PCPG immune signature was validated with NanoString immune panel in an independent cohort. Unsupervised clustering of the immune infiltration scores from CIBERSORT was used to find immune clusters. A prognostic immune score model for PCPGs and the other NENs were calculated as a linear combination of the estimated infiltration of activated CD8+/CD4+ T cells, activated NK cells, and M0 and M2 macrophages. Results: In PCPGs, we found five dominant immune clusters, associated with M2 macrophages, monocytes, activated NK cells, M0 macrophages and regulatory T cells, and CD8+/CD4+ T cells respectively. Non-metastatic tumors were associated with activated NK cells and metastatic tumors were associated with M0 macrophages and regulatory T cells. In GEPNETs and SCLCs, M0 macrophages and regulatory T cells were associated with unfavorable outcomes and features, such as metastasis and high-grade tumors. The prognostic immune score model for PCPGs and the NENs could predict non-aggressive and non-metastatic diseases. In PCPGs, the immune score was also an independent predictor of metastasis-free survival in a multivariate Cox regression analysis. Conclusion: The transcriptomic immune signature in PCPG correlates with clinical features like metastasis and prognosis.
AB - Purpose: To understand prognostic immune cell infiltration signatures in neuroendocrine neoplasms (NENs), particularly pheochromocytoma and paraganglioma (PCPG), we analyzed tumor transcriptomic data from The Cancer Genome Atlas (TCGA) and other published tumor transcriptomic data of NENs. Methods: We used CIBERSORT to infer immune cell infiltrations from bulk tumor transcriptomic data from PCPGs, in comparison to gastroenteropancreatic neuroendocrine tumors (GEPNETs) and small cell lung carcinomas (SCLCs). PCPG immune signature was validated with NanoString immune panel in an independent cohort. Unsupervised clustering of the immune infiltration scores from CIBERSORT was used to find immune clusters. A prognostic immune score model for PCPGs and the other NENs were calculated as a linear combination of the estimated infiltration of activated CD8+/CD4+ T cells, activated NK cells, and M0 and M2 macrophages. Results: In PCPGs, we found five dominant immune clusters, associated with M2 macrophages, monocytes, activated NK cells, M0 macrophages and regulatory T cells, and CD8+/CD4+ T cells respectively. Non-metastatic tumors were associated with activated NK cells and metastatic tumors were associated with M0 macrophages and regulatory T cells. In GEPNETs and SCLCs, M0 macrophages and regulatory T cells were associated with unfavorable outcomes and features, such as metastasis and high-grade tumors. The prognostic immune score model for PCPGs and the NENs could predict non-aggressive and non-metastatic diseases. In PCPGs, the immune score was also an independent predictor of metastasis-free survival in a multivariate Cox regression analysis. Conclusion: The transcriptomic immune signature in PCPG correlates with clinical features like metastasis and prognosis.
KW - Biomarkers
KW - Immunologic signature
KW - Metastasis
KW - Paraganglioma
KW - Pheochromocytoma
UR - http://www.scopus.com/inward/record.url?scp=85141741022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141741022&partnerID=8YFLogxK
U2 - 10.1007/s12020-022-03218-1
DO - 10.1007/s12020-022-03218-1
M3 - Article
C2 - 36370152
AN - SCOPUS:85141741022
SN - 1355-008X
VL - 79
SP - 171
EP - 179
JO - Endocrine
JF - Endocrine
IS - 1
ER -